2seventy bio (TSVT) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for 2seventy bio (NASDAQ: TSVT):

• 3/14/2025 – 2seventy bio had its price target lowered by analysts at Morgan Stanley from $6.00 to $5.00. They now have an “equal weight” rating on the stock.
• 3/11/2025 – 2seventy bio had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $5.00 price target on the stock, down previously from $9.00.
• 3/11/2025 – 2seventy bio was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 3/7/2025 – 2seventy bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 2/19/2025 – 2seventy bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 2/1/2025 – 2seventy bio had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

2seventy bio Stock Performance

TSVT stock opened at $4.96 on Thursday. The stock has a market cap of $255.88 million, a PE ratio of -2.67 and a beta of 1.73. The stock has a 50-day moving average price of $2.85 and a two-hundred day moving average price of $3.69. 2seventy bio, Inc. has a 1 year low of $2.29 and a 1 year high of $5.99.

Insider Activity

In other news, CEO William D. Baird III sold 5,092 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $25,205.40. Following the completion of the transaction, the chief executive officer now owns 1,121,034 shares in the company, valued at $5,549,118.30. This trade represents a 0.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total value of $25,350,607.23. The disclosure for this sale can be found here. Insiders sold 5,152,093 shares of company stock worth $25,400,018 in the last quarter. Corporate insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On 2seventy bio

A number of institutional investors have recently bought and sold shares of TSVT. GSA Capital Partners LLP acquired a new position in 2seventy bio during the third quarter worth approximately $64,000. Intech Investment Management LLC acquired a new position in 2seventy bio during the third quarter worth approximately $69,000. FMR LLC increased its position in 2seventy bio by 22.0% during the third quarter. FMR LLC now owns 148,545 shares of the company’s stock worth $701,000 after buying an additional 26,738 shares during the last quarter. BBR Partners LLC increased its position in 2seventy bio by 620.0% during the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after buying an additional 155,000 shares during the last quarter. Finally, PDT Partners LLC acquired a new position in 2seventy bio during the third quarter worth approximately $244,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.